share_log

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

HC Wainwright & Co.维持对theravance biopharma 的买入评级,将价格目标下调至15美元。
Benzinga ·  08/06 15:02  · 评级/大行评级

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $20 to $15.

HC Wainwright & Co.分析师Douglas Tsao维持对theravance biopharma(纳斯达克:TBPH)的买入评级,将目标价从20美元下调至15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发